Research Focus Areas
Custom Synthesis of Metal/Porous Nanoparticles
Nanotoxicology
Biomedical Image Contrast Agents
Precision Nanoprobes
Molecular Nanotechnology
Custom Synthesis of Metal/Porous Nanoparticles
Standardized synthesis of Gold nanoparticles (nanoclusters, 5 nm, 10 nm, 16 nm) Silver nanoparticles (nanoclusters, 10 nm, 40 nm, 95 nm) Iron oxide nanoparticles (10 nm) Gadolinium oxide (5 nm, 10 nm) Hafnium oxide (5 nm, 10 nm) Microporous silica particles (15 nm, 50 nm, 100 nm, 400 nm) Other nanoparticles currently being optimized include …
Nanotoxicology
Nanotoxicity assessment is an integral part of designing biomedical probes. In vitro toxicity of nanoparticles is assessed using murine (L929) and human cell lines (HUVEC, RAW246.7). In vivo toxicity was assessed in zebrafish models, and in vivo biodistribution/blood pool kinetics was assessed in athymic and euthymic mouse models. Representative Publications …
Biomedical Image Contrast Agents
Scaled up the synthesis of nanoparticle contrast agents. I specialize in the synthesis of long emission lifetime, fluorescent and photoluminescent nanoparticles. This is achieved by modifying Au cores with fluorophore embedded shells or Au nanoclusters with tunable photoluminescence. Fluorescent silica particles with sizes ranging from 15 nm to 400 nm are also available. Such probes …
Precision Nanoprobes
Antibody-drug conjugates are emerging as a frontrunner in precision targeted therapeutics. However, this capability is still beyond the ability of most academic laboratories. The primary reason for this is the need to identify a precise binding site on the constant region of the antibody (Fc) for the drug molecule to be conjugated, while not affecting …
Molecular Nanotechnology
This is the current focus of my research. Utilizing anisotropic and hybrid nanoparticle architectures to introduce directionality in motion, precisely orienting targeting molecules and directed exertion of force by nanosystems. Anisotropic nanoparticles can be Janus hybrids or non-spherical nanoparticles and include rods, plates, prisms, and core-shells. This will lay the basis for nanomotors and nanomachines …
Nallathamby Lab Presents Phage-Mimicking Antibacterial Nanoparticle Results at Military Health Sciences Research Symposium 2022 in Orlando, Florida (Sept 12-15, 2022)
We are losing in an antibiotic arms race with bacteria due to the emergence and global spread of new antibiotic resistance mechanisms.1,2 At current rates of antibiotics discovery and development we will eventually lose to antibiotic-resistant strains, and by 2050, antibiotics resistant strains of bacteria will kill more patients per year than all cancers combined. …
CTSI-Think Tank Seed Funds our Efforts to facilitate CAR-T Therapy to Treat Solid Tumors.
Breast Cancer is the most widespread cancer and the second leading cause of cancer-related deaths among women in the U.S.A. As a treatment option, gene-modified T cells are under active therapeutic consideration for both hematological and solid malignancies. As of 2016, there are 17 active TCR and 103 ongoing CAR-modified T cell studies registered through …
NIH Funding Opportunities
- Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical Trial Not Allowed) February 8, 2023Funding Opportunity RFA-DA-24-027 from the NIH Guide for Grants and Contracts. This concept proposes to advance methodological rigor in NIDA-relevant research by supporting training on the responsible analyses of complex, large-scale datasets involving brain, behavioral, genomic, and socioenvironmental data through: 1. Courses for Skills Development 2. Curriculum or Methods Development
- Clinical Trials Results Information Submission: Good Cause Extension Request Process and Criteria Document Posted on ClinicalTrials.gov February 8, 2023Notice NOT-OD-23-080 from the NIH Guide for Grants and Contracts
- Notice of Early Expiration of NINDS BRAIN Initiative Funding Opportunity Announcements (FOA) RFA-NS-21-026 and RFA-NS-21-027 February 8, 2023Notice NOT-NS-23-037 from the NIH Guide for Grants and Contracts
- Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative: Optimization of Instrumentation and Device Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed) February 8, 2023Notice NOT-NS-23-036 from the NIH Guide for Grants and Contracts
- Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) February 8, 2023Notice NOT-NS-23-035 from the NIH Guide for Grants and Contracts
- Notice of Participation of NIMH in PAR-21-169, "Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)" February 8, 2023Notice NOT-MH-23-185 from the NIH Guide for Grants and Contracts
- Notice of Participation of NIMH in PAR-21-173, "Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed) February 8, 2023Notice NOT-MH-23-186 from the NIH Guide for Grants and Contracts
- Notice of Participation of NIMH in PAR-22-080, Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed) February 8, 2023Notice NOT-MH-23-190 from the NIH Guide for Grants and Contracts
- Notice of Special Interest (NOSI): Discovery of the Genetic Basis of Conditions Associated with Down Syndrome for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project (X01) February 8, 2023Notice NOT-OD-23-042 from the NIH Guide for Grants and Contracts
- Notice of NHGRI Participation in the National Science Foundation Molecular Foundations for Biotechnology (MFB) Partnerships to Transform Emerging Industries - RNA Tools/Biotechnology February 8, 2023Notice NOT-HG-23-020 from the NIH Guide for Grants and Contracts
Recent Comments